Business Update Neutral

2026-11-05 20:26

- Audio recording of earnings conference call held for Q2 and H1 ended September 30, 2026, is available on the company's website.

Business Update Neutral

2026-11-05 20:13

- Audio recording of the earnings conference call held for Q2 and H1 ended September 30, 2026, has been made available on the company's website. - Link: https://bluejethealthcare.com/investor-presentation/

Routine Neutral

2026-11-05 16:11

New Filing detected. See link for details.

Routine Neutral

2026-11-05 16:09

New Filing detected. See link for details.

Routine Neutral

2026-11-05 12:58

New Filing detected. See link for details.

Routine Neutral

2026-11-05 12:56

New Filing detected. See link for details.

Routine Neutral

2026-11-05 12:53

New Filing detected. See link for details.

Business Update Neutral

2026-10-29 13:39

Concall Schedule Concall Date: November 05, 2026 Concall Time: 5:00 PM IST

Governance Neutral

2026-10-29 13:33

- Board Meeting scheduled on Thursday, November 5, 2026. - Agenda: Consider and approve Unaudited Standalone Financial Results for the quarter and half year ended September 30, 2026. - Trading window will reopen on November 8, 2026.

Business Update Neutral

2026-10-29 13:26

Concall Schedule Concall Date: November 05, 2026 Concall Time: 5:00 PM IST

Routine Neutral

2026-09-24 16:32

- Trading window closed for Designated Persons and immediate relatives effective October 1, 2026. - Closure will remain until 48 hours after declaration of Unaudited Financial Results for the quarter and half year ended September 30, 2026.

Governance Positive

2026-09-22 20:54

- Voting results of the 58th Annual General Meeting held on September 21, 2026, were announced. - All resolutions were passed, including the adoption of the Audited Standalone Financial Statements for the financial year ended March 31, 2026. - A dividend of Re. 1.20 (One Rupee and Twenty paise only) per share for the financial year ended March 31, 2026, was declared and approved. - Re-appointments of Mr. Naresh Suryakant Shah, Mr. Akshay Bansarilal Arora, and Mr. Shiven A. Arora as directors, and M/s. KKC & Associates LLP as Statutory Auditors were approved.

Governance Positive

2026-09-21 13:22

- The 58th Annual General Meeting (AGM) of Blue Jet Healthcare Limited was held on September 21, 2026, at 11:00 AM via Video Conferencing. - Shareholders adopted the Audited Standalone Financial Statements for the financial year ended March 31, 2026. - A dividend of Re.1.20 per share was declared for the financial year ended March 31, 2026. - Re-appointments included Mr. Naresh Suryakant Shah (Director), M/s. KKC & Associates LLP (Statutory Auditors), Mr. Akshay Bansarilal Arora (Whole-Time Director & Executive Chairman), and Mr. Shiven A. Arora (Managing Director). - The Auditor's Report for FY26 had no qualifications, reservations, or adverse remarks.

Business Update Positive

2026-08-18 14:20

- Blue Jet Healthcare Limited submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26. - The report highlights an increase in renewable energy consumption from 26,321.38 GJ (FY24-25) to 40,836.79 GJ (FY25-26). - Scope 1 and Scope 2 GHG emissions were reduced from 34,885.47 tCO2 (FY24-25) to 32,138.47 tCO2 (FY25-26). - The company implemented a Zero Liquid Discharge (ZLD)-based water management system and recycled 48,827 KL of water in FY25-26.

Business Update Positive

2026-08-18 13:49

- Blue Jet Healthcare Limited submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26. - The report highlights increased renewable energy consumption and a reduction in Scope 1 and Scope 2 GHG emissions. - No stakeholder complaints were filed or pending for FY25-26. - The company's FY25-26 turnover was ₹9,473.21 million and net worth was ₹13,599.12 million.

Business Update Positive

2026-08-07 10:41

- Q1 FY27 saw revenue from operations of INR293 crores (▲25% sequentially) and operating EBITDA of INR98 crores (▲3% sequentially to 33.5% margin), reflecting healthy sequential improvement. - Gross margin reduced by 3% sequentially to 53% and PAT marginally declined QoQ, primarily due to increased raw material prices and product mix, as well as lower other income. - INR30 crores of Contrast Media sales were delayed due to transit issues and are expected to be recognized in Q2. - Hyderabad R&D center is expected to be operational this month, and the Unit 3 backward integration project for contrast media intermediates is ahead of schedule, expected to contribute commercially in H2 FY27. - The Vizag project, with an investment of approximately INR1,000 crores over three years, has commenced to expand manufacturing and innovation capabilities across GMP intermediates, complex APIs, and CDMO. - Management expects to launch 3 new Contrast Media candidates and initiate pilot activities for a new high-intensity sweetener in FY27, with strong visibility for the PI API segment over the next 3-4 quarters. - The company focuses on platform diversification into new areas like peptide fragments and GLP-1 intermediates, pursuing a selective CDMO model. - Long-term capital expenditure is guided at approximately INR1,000 crores over the next three years, with INR250 crores expected in FY27.

Business Update Positive

2026-08-07 10:36

- Q1 FY27 saw an encouraging start with improved sequential business momentum, driven by stronger performance in the PI and API segments.- Hyderabad R&D center expected to be operational in August 2026; Unit 3 backward integration for contrast media intermediates on track for H2 FY27 commercial contribution.- Vizag project execution commenced, with an investment of ~INR1,000 crores over 3 years (~INR250 crores in FY27), targeting expanded manufacturing, new sweetener capacity, and an intermediate cluster.- Management has strong visibility for the PI/API segment for the next 3-4 quarters and expects to launch 3 Contrast Media candidates and initiate a new high-intensity sweetener pilot in FY27.- Long-term strategy focuses on building an innovation-led CDMO platform and platform diversification, with commercialization from Vizag expected from late FY29 to FY30.

Business Update Neutral

2026-08-03 20:54

- Submission of audio recording of the earnings conference call held to discuss financial results for the quarter ended June 30, 2026. - The recording is available on the company's website: https://bluejethealthcare.com/investor-presentation/

Business Update Neutral

2026-08-03 20:45

- Audio recording of the earnings conference call held on August 03, 2026, to discuss financial results for the quarter ended June 30, 2026, is available on the company's website.

Financials Negative

2026-08-03 15:22

- Consolidated Revenue ₹2,931Mn vs ₹3,548Mn (▼17% YoY) - EBITDA ₹981Mn vs ₹1,210Mn (▼19% YoY) - PAT ₹783Mn vs ₹912Mn (▼14% YoY) - EBITDA Margin 33% vs 34% (▼100bps) - The decrease in revenue from operations during Q1 FY27 was primarily due to lower sales in the PI (Pharma Intermediates) category. - Company successfully completed fund raising aggregating to ₹8,000 million by allotting equity shares to QIBs. - R&D center at Hyderabad and Vizag project activities are progressing as planned.

Financials Negative

2026-08-03 12:56

- Standalone Revenue ₹2,931.13Mn vs ₹3,547.58Mn (▼17.37% YoY) - EBITDA ₹1,133.12Mn vs ₹1,292.48Mn (▼12.33% YoY) - PAT ₹782.64Mn vs ₹911.70Mn (▼14.16% YoY) - EBITDA Margin 38.66% vs 36.43% (▲223bps) - Board approved re-appointment of Mr. Akshay B Arora as Whole Time Director & Executive Chairman for 5 years. - Board approved re-appointment of Mr. Shiven Akshay Arora as Managing Director for 5 years. - Board approved re-appointment of M/s KKC & Associates LLP as Statutory Auditors for a second term of 5 years. - Board declared a dividend of ₹1.2/- per equity share (@60%) for FY 2025-26. - 58th Annual General Meeting (AGM) to be held on September 21, 2026.

Financials Negative

2026-08-03 12:53

- Standalone Revenue ₹293.11 Cr vs ₹354.76 Cr (▲-17.4% YoY) - Standalone EBITDA ₹98.08 Cr vs ₹120.99 Cr (▲-18.9% YoY) - Standalone PAT ₹78.26 Cr vs ₹91.17 Cr (▲-14.2% YoY) - Standalone EBITDA Margin 33.46% vs 34.11% (▼65 bps) - Board declared a dividend of ₹1.2/- per Equity Share (60% on face value of ₹2/-) for FY 2025-26, with record date September 14, 2026. - Re-appointment of Mr. Akshay B Arora as Whole Time Director & Executive Chairman for five years. - Re-appointment of Mr. Shiven Akshay Arora as Managing Director for five years. - Re-appointment of M/s KKC & Associates LLP as Statutory Auditors for a second term of five years. - 58th Annual General Meeting (AGM) to be held on September 21, 2026.

Financials Negative

2026-08-03 12:52

- Standalone Revenue ₹2,931.13 Mn vs ₹3,547.58 Mn (▼17.4% YoY) - EBITDA ₹980.75 Mn vs ₹1,209.94 Mn (▼18.8% YoY) - PAT ₹782.64 Mn vs ₹911.70 Mn (▼14.2% YoY) - EBITDA Margin 33.46% vs 34.11% (▼65 bps)

Financials Negative

2026-08-03 12:52

- Standalone Revenue ₹293.11 Cr vs ₹354.76 Cr (▼17% YoY) - EBITDA ₹98.08 Cr vs ₹121.00 Cr (▼19% YoY) - PAT ₹78.26 Cr vs ₹91.17 Cr (▼14% YoY) - EBITDA Margin 33.46% vs 34.11% (▼65bps) - Board approved a Dividend of ₹1.2/- per Equity Share for FY 2025-26, with record date September 14, 2026. - Re-appointed Mr. Akshay B Arora as Whole Time Director & Executive Chairman and Mr. Shiven Akshay Arora as Managing Director, both for 5-year terms. - Re-appointed M/s KKC & Associates LLP as Statutory Auditors for a second 5-year term. - Subsequent to the quarter end, the company successfully raised ₹8,000.00 million through a Qualified Institutional Placement (QIP).

Financials Negative

2026-08-03 12:50

- Standalone Revenue ₹293.11Cr vs ₹354.76Cr (▼17.38% YoY) - EBITDA ₹98.08Cr vs ₹121.00Cr (▼18.94% YoY) - PAT ₹78.26Cr vs ₹91.17Cr (▼14.15% YoY) - EBITDA Margin 33.46% vs 34.11% (▼65bps) - Board recommended a dividend of ₹1.2/- per equity share for FY 2025-26. - Re-appointment of Mr. Akshay B Arora as Whole Time Director and Executive Chairman for 5 years. - Re-appointment of Mr. Shiven Akshay Arora as Managing Director for 5 years. - Re-appointment of M/s KKC & Associates LLP as Statutory Auditors for 5 years. - The 58th Annual General Meeting (AGM) will be held on September 21, 2026.

Financials Negative

2026-08-03 12:49

- Standalone Revenue ₹2,931.13 million vs ₹3,547.58 million (▼17.37% YoY) - Standalone EBITDA ₹980.75 million vs ₹1,209.94 million (▼18.94% YoY) - Standalone PAT ₹782.64 million vs ₹911.70 million (▼14.15% YoY) - Standalone EBITDA Margin 33.46% vs 34.11% (▼65bps)

Financials Negative

2026-08-03 12:48

- Standalone Revenue ₹293.11Cr vs ₹354.76Cr (▼17.37% YoY) - EBITDA ₹98.08Cr vs ₹120.99Cr (▼18.94% YoY) - PAT ₹78.26Cr vs ₹91.17Cr (▼14.16% YoY) - EBITDA Margin 33.46% vs 34.11% (▼65bps) - Board approved re-appointment of Mr. Akshay B Arora as Whole Time Director and Executive Chairman for 5 years, and Mr. Shiven Akshay Arora as Managing Director for 5 years, effective April 13, 2027. - Re-appointment of M/s KKC & Associates LLP as Statutory Auditors for a second term of 5 years until the 63rd AGM (FY2030-31). - Declared a dividend of ₹1.2/- per equity share (60%) for the financial year 2025-26, with a record date of September 14, 2026. - The 58th Annual General Meeting (AGM) will be held on September 21, 2026.

Financials Negative

2026-08-03 12:47

- Standalone Revenue ₹2,931.13 Mn vs ₹3,547.58 Mn (▼17.38% YoY) - EBITDA ₹980.75 Mn vs ₹1,209.94 Mn (▼18.94% YoY) - PAT ₹782.64 Mn vs ₹911.70 Mn (▼14.15% YoY) - EBITDA Margin 33.46% vs 34.11% (▼65 bps)

Financials Negative

2026-08-03 12:46

- Standalone Operating Revenue ₹293.11Cr vs ₹354.76Cr (▼17.4% YoY) - EBITDA ₹98.08Cr vs ₹120.99Cr (▼18.9% YoY) - PAT ₹78.26Cr vs ₹91.17Cr (▼14.1% YoY) - EBITDA Margin 33.46% vs 34.11% (▼65bps)

Business Update Neutral

2026-07-28 15:34

- Concall Schedule - Concall Date: Monday, August 03, 2026 - Concall Time: 5:30 PM IST - To discuss Unaudited Standalone Financial Results for the quarter ended June 30, 2026.

Business Update Neutral

2026-07-28 15:20

- Concall Schedule - Concall Date: Monday, August 03, 2026 - Concall Time: 5:30 PM (IST)

Governance Neutral

2026-07-28 15:05

- Board meeting scheduled for August 03, 2026. - To approve Unaudited Standalone Financial Results for the quarter ended June 30, 2026. - Trading window to remain closed until August 06, 2026.

Business Update Positive

2026-07-20 15:02

- Blue Jet Healthcare Limited received the EcoVadis Silver Medal for outstanding sustainability management practices, effective July 20, 2026. - The company ranks among the top 15% globally with a 90th percentile ranking in sustainability performance. - Achieved an EcoVadis Sustainability Score of 77 out of 100.

Business Update Positive

2026-07-20 14:59

- Blue Jet Healthcare Limited awarded 'Silver Medal' by EcoVadis for outstanding sustainability management practices, effective July 20, 2026. - Ranks among the top 15% globally with a 90th percentile ranking in sustainability performance. - Achieved an EcoVadis Sustainability Score of 77 out of 100. - Recognition highlights strong environmental, social, ethical, and governance practices.

Routine Neutral

2026-07-09 22:52

New Filing detected. See link for details.

Routine Neutral

2026-07-09 22:47

New Filing detected. See link for details.

Routine Neutral

2026-07-09 20:09

New Filing detected. See link for details.

Routine Neutral

2026-07-09 20:03

New Filing detected. See link for details.

Business Update Positive

2026-07-06 19:46

- Blue Jet Healthcare Limited is undertaking a Qualified Institutions Placement (QIP) of equity shares. - The Investment and Finance Committee approved the preliminary placement document and authorized the opening of the Issue on July 6, 2026. - The floor price for the Issue has been fixed at ₹531.70 per Equity Share. - The company may offer a discount of not more than 5% on the floor price.

Business Update Positive

2026-07-06 19:45

- Blue Jet Healthcare Limited announced the Qualified Institutions Placement (QIP) of equity shares. - The Investment and Finance Committee, on July 6, 2026, approved the preliminary placement document and set the floor price at ₹531.70 per Equity Share. - The QIP issue opened on July 6, 2026, with a potential discount of up to 5% on the floor price.

Financials Negative

2026-07-06 15:57

CRITICAL RED FLAG DETECTED

- Submission of Audited Standalone Financial Statements for the Financial Year ended March 31, 2026, approved by the Board on May 25, 2026. - Auditors (KKC & Associates LLP) noted disputed income tax liabilities totaling approx. ₹1768.86 million (net of deposits) for AY 2020-21 to 2023-24. - Internal control weaknesses were identified regarding audit trails: inventory records were manual in spreadsheets without audit trail up to December 7, 2025, and the auditor was unable to comment on the audit trail for third-party payroll software. - Title deeds for certain immovable properties (leasehold land and building) are still in the process of being transferred to the company after amalgamation/merger.

Financials Neutral

2026-07-06 14:55

- Submitted Audited Standalone Financial Statements for FY26 with an unqualified audit opinion. - Board proposed final dividend for FY26. - Auditors noted manual inventory records, pending property title transfers, and significant disputed income tax dues for various assessment years.

Financials Neutral

2026-07-06 14:55

- Board approved audited standalone financial statements for FY ended March 31, 2026, on May 25, 2026. - Independent Auditor's Report by KKC & Associates LLP gives a "true and fair view" opinion. - A final dividend for FY 2025-26 has been proposed by the Board, subject to shareholder approval (amount not specified in this filing). - Detailed financial figures (Revenue, EBITDA, PAT) for comparison are not provided in this specific filing.

Ownership Neutral

2026-06-25 13:28

- Trading window closed for Designated Persons and their immediate relatives as per SEBI (Prohibition of Insider Trading) Regulations, 2015. - Effective from July 1, 2026, until 48 hours after the declaration of Unaudited Standalone Financial Results for the first quarter ended June 30, 2026.

Routine Neutral

2026-06-25 13:21

- Trading window for Designated Persons and their immediate relatives will remain closed. - Closure effective from July 1, 2026. - The window will re-open 48 hours after the declaration of Unaudited Standalone Financial Results for Q1 ended June 30, 2026.

Governance Positive

2026-06-18 16:29

- Blue Jet Healthcare Limited announced the voting results of its EGM held on June 17, 2026. - A special resolution to approve raising of funds via issuance of Equity Shares and/or other Eligible Securities was passed with 99.9999% votes in favor.

Governance Positive

2026-06-18 16:20

- Voting results and Scrutinizer's Report of the Extra-Ordinary General Meeting (EGM) held on June 17, 2026. - The resolution to approve raising of funds in one or more tranches, by issuance of Equity Shares and/or other Eligible Securities, was passed with 99.9999% votes in favour.

Governance Neutral

2026-06-17 12:23

- An Extra-Ordinary General Meeting (EGM) of Blue Jet Healthcare Limited was held on June 17, 2026, at 11:00 AM via Video Conferencing/OAVM. - The key agenda item was to consider and approve raising of funds by issuance of Equity Shares and/or other Eligible Securities through a special resolution. - E-voting facilities were provided, and the results of the voting will be declared within the stipulated time. - The meeting concluded at 11:29 AM IST.

Governance Neutral

2026-06-17 12:12

- Proceedings of the Extra-Ordinary General Meeting (EGM) of Blue Jet Healthcare Limited held on June 17, 2026, at 11:00 AM via Video Conferencing (VC)/Other Audio Visual Means (OAVM). - The EGM was convened to consider and approve raising of funds in one or more tranches through the issuance of Equity Shares and/or other Eligible Securities. - E-voting results are yet to be declared and will be submitted to stock exchanges and made available on the Company's website.

Routine Neutral

2026-06-15 11:41

- Blue Jet Healthcare responded to BSE and NSE regarding significant volume movement observed in its security. - The company confirmed it has made all necessary disclosures as per SEBI Listing Regulations, 2015. - The increase in volume is attributed entirely to market conditions, over which the Company has no control.

Business Update Neutral

2026-06-12 18:25

- Blue Jet Healthcare clarified significant volume movement in its security, attributing it to market conditions beyond its control. - The company confirmed timely disclosures in compliance with SEBI Listing Regulations, 2015.

Routine Neutral

2026-06-12 18:24

- Blue Jet Healthcare Limited responded to an email from BSE/NSE dated June 12, 2026, regarding significant volume movement in its shares. - The company stated all necessary disclosures were made, and volume movement is due to market conditions.

Routine Neutral

2026-06-09 18:17

New Filing detected. See link for details.

Routine Neutral

2026-06-09 18:08

New Filing detected. See link for details.

Business Update Positive

2026-05-29 16:55

Blue Jet Healthcare described FY26 as a foundational year with significant investments, despite a decline in overall revenue and muted EBITDA primarily due to PI/API destocking. For FY27, management guided for double-digit growth in the contrast media segment, driven by 3-4 new product launches and backward integration. The PI segment is expected to recover and exceed FY25 peak levels as inventory destocking normalizes. The company plans a capex of approximately INR 1,000 crores over 3 years for the Vizag greenfield project and INR 40 crores for a new Hyderabad R&D center, targeting peptide-related intermediates and GLP-1 opportunities. Blue Jet Healthcare remains debt-free with strong liquidity, expecting improved business visibility and commercialization of new products in FY27.

Business Update Positive

2026-05-29 16:47

Management highlighted FY26 as a foundational year, with destocking in the PI/API segment largely behind, leading to improved visibility and confirmed orders. They expect double-digit growth in contrast media for FY27, supported by new product launches. A significant long-term growth platform is underway with INR1,000 crores capex for the Vizag greenfield project over 3 years, with Phase 1 production starting in H2 FY27. An R&D center in Hyderabad (INR40 crores) will focus on new chemistry platforms, including peptides. The company is debt-free with INR400 crores in liquid assets.

Governance Positive

2026-05-27 16:23

Blue Jet Healthcare Limited has submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report, issued by Mehta and Mehta, Company Secretaries, confirms the company's full compliance with all applicable SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other relevant SEBI regulations and secretarial standards. No non-compliances, regulatory actions, or auditor resignations were observed during the review period.

Governance Positive

2026-05-26 15:12

Blue Jet Healthcare Limited announced an Extra-Ordinary General Meeting (EGM) to be held on June 17, 2026, through Video Conferencing. The EGM will seek shareholder approval to raise funds up to ₹10,000 million (₹1000 Crores) through the issuance of Equity Shares and/or other Eligible Securities, which may include Qualified Institutions Placement (QIP).

Business Update Neutral

2026-05-25 17:30

Blue Jet Healthcare Limited announced the submission of the audio recording of its earnings conference call, held to discuss the financial results for the quarter and financial year ended March 31, 2026. The recording is accessible on the company's website as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Routine Neutral

2026-05-25 12:43

New Filing detected. See link for details.

Governance Positive

2026-05-25 12:41

The Board of Directors of Blue Jet Healthcare Limited approved Audited Standalone Financial Results for Q4 FY26, reporting Revenue of ₹340.45 Cr (▲44.40% YoY), EBITDA of ₹139.97 Cr (▲96.40% YoY), and PAT of ₹110.10 Cr (▲71.10% YoY). EBITDA Margin expanded by 1074 bps to 41.11%. The Board also recommended a final dividend of ₹1.2 per share for FY26 and approved a proposal to raise funds up to ₹1,000 Cr through various instruments, subject to EGM approval on June 17, 2026.

Financials Positive

2026-05-25 12:40

Standalone Revenue ₹3,404.45Mn vs ₹2,346.68Mn (▲44.15% YoY), EBITDA ₹1,409.68Mn vs ₹712.67Mn (▲97.80% YoY), PAT ₹1,100.95Mn vs ₹643.44Mn (▲71.10% YoY) for the quarter ended March 31, 2026. EBITDA Margin 41.41% vs 30.37% (▲1104bps). The Board also recommended a final dividend of ₹1.2 per equity share for FY26 and proposed to raise funds up to ₹10,000 million (₹1,000 Cr) through various instruments, subject to shareholder approval.

Routine Neutral

2026-05-19 12:08

New Filing detected. See link for details.

BLUEJET

Blue Jet Healthcare Limited

Price Chart

Filing History

Unlock Full History